المؤلفون: Meng, Yang, Hertel, Nadine, Ellis, John, Morais, Edith, Johnson, Helen, Philips, Zoe, Roskell, Neil, Walker, Andrew, Lee, Dawn

المصدر: Meng , Y , Hertel , N , Ellis , J , Morais , E , Johnson , H , Philips , Z , Roskell , N , Walker , A & Lee , D 2018 , ' The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ' , The European Journal of Health Economics , vol. 19 , no. 8 , pp. 1163-1172 . https://doi.org/10.1007/s10198-018-0964-4Test

مصطلحات موضوعية: Age Factors, Aged, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/economics, Cost-Benefit Analysis, Dacarbazine/economics, Disease Progression, Disease-Free Survival, Female, Health Expenditures, Health Resources/economics, Humans, Imidazoles/economics, Ipilimumab/economics, Kaplan-Meier Estimate, Male, Markov Chains, Melanoma/drug therapy, Middle Aged, Models, Economic, Nivolumab/administration & dosage, Oximes/economics, Proto-Oncogene Proteins B-raf/genetics, Quality-Adjusted Life Years, Sex Factors, Skin Neoplasms/drug therapy, Vemurafenib/economics

الإتاحة: https://doi.org/10.1007/s10198-018-0964-4Test
https://research.manchester.ac.uk/en/publications/26e5682b-09e9-48c9-95bb-92588f8e8987Test

المؤلفون: Yang Meng, Neil Roskell, Andrew Walker, Helen Johnson, D. Lee, John Ellis, Zoe Philips, N. Hertel, E. Morais

المصدر: Meng, Y, Hertel, N, Ellis, J, Morais, E, Johnson, H, Philips, Z, Roskell, N, Walker, A & Lee, D 2018, ' The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ', The European Journal of Health Economics, vol. 19, no. 8, pp. 1163-1172 . https://doi.org/10.1007/s10198-018-0964-4Test

مصطلحات موضوعية: Male, Oncology, Skin Neoplasms, Cost effectiveness, Cost-Benefit Analysis, Economics, Econometrics and Finance (miscellaneous), Kaplan-Meier Estimate, Antineoplastic Agents, Immunological, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Skin Neoplasms/drug therapy, Melanoma/drug therapy, 030212 general & internal medicine, Vemurafenib, Melanoma, Health Policy, Imidazoles, Age Factors, Ipilimumab/economics, Middle Aged, Markov Chains, Nivolumab/administration & dosage, Dacarbazine, Nivolumab, Models, Economic, Health Resources/economics, 030220 oncology & carcinogenesis, Disease Progression, Health Resources, Female, Quality-Adjusted Life Years, medicine.drug, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Imidazoles/economics, Ipilimumab, Disease-Free Survival, 03 medical and health sciences, Sex Factors, Antineoplastic Agents, Immunological/administration & dosage, Internal medicine, Proto-Oncogene Proteins B-raf/genetics, medicine, Humans, Oximes/economics, Survival analysis, Aged, business.industry, Vemurafenib/economics, Dacarbazine/economics, Dabrafenib, Clinical trial, Health Expenditures, business, Antineoplastic Combined Chemotherapy Protocols/economics

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbba7ec0a8309e03b0b8e6ffb8f01a95Test
https://doi.org/10.1007/s10198-018-0964-4Test